Noteworthy Monday Option Activity: RH, HIMS, CYTK

Hims & Hers (HIMS) saw unusually large options activity with 84,932 contracts traded (≈8.5 million underlying shares), equal to roughly 61.1% of its one‑month average daily volume of 13.9 million shares; the March 20, 2026 $40 call accounted for 7,392 contracts (≈739,200 shares). Cytokinetics (CYTK) logged 10,200 option contracts (≈1.0 million underlying shares), or about 58.4% of its one‑month average daily volume of 1.7 million shares, led by 3,211 contracts in the Jan 16, 2026 $75 call (≈321,100 shares). The concentrated call flows and high notional exposure suggest significant directional positioning that could affect intraday price moves and implied volatility for both small‑cap healthcare names.

Analysis

Market structure: The concentrated call flow in HIMS (84,932 contracts ≈ 8.5M shares, ~61% of 1‑month ADV) and CYTK (10,200 contracts ≈ 1.0M shares, ~58% of ADV) likely reflects directional, institutional or volatility-driven positioning rather than retail pinning — dealers selling calls will carry positive gamma hedging that can lift underlying prices into expiries (notably Mar‑20‑2026 $40 HIMS and Jan‑16‑2026 $75 CYTK). Winners are long‑option buyers, short‑gamma dealers temporarily; losers are liquidity providers if forced into large dynamic hedges. Cross‑asset: sustained buy‑flow could modestly tighten corporate credit spreads for these small caps (sentiment proxy) and lift USD risk sentiment minimally; bond/commodity impact is negligible absent broader health‑sector moves.

Risk assessment: Tail risks include adverse clinical/regulatory events (FDA setbacks for CYTK drug candidates or consumer‑health regulatory action for HIMS) that could wipe out option premiums; a single negative catalyst could trigger >40% downside within days. Immediate (days) risk is volatility spikes and gamma squeezes; short term (weeks–months) is IV mean reversion; long term (quarters–years) depends on fundamentals (HIMS subscriber growth, CYTK trial readouts). Hidden dependency: flow may be directional hedge for larger equity exposure elsewhere, so unwind could be abrupt; monitor changes in open interest and dealer put/call skew. Catalysts: earnings, trial updates, and any block trade reporting within 30–90 days.

Trade implications: Direct: initiate a small, structured exposure rather than naked directional: for HIMS, consider a Mar‑2026 call debit spread (long $35 / short $45) sized 1–2% of NAV to capture upside while capping premium paid; for CYTK, consider Jan‑2026 $60/$80 call spread at 1% NAV or a cheaper long‑dated call if bullish. Pair: long HIMS equity vs short TDOC (Teladoc, TDOC) 0.5:1 notional to play consumer telehealth share gains vs enterprise telemedicine execution risk. Options: avoid selling naked calls into elevated demand; instead sell short‑dated (30–60 day) call credit spreads only after IV compression >5 vol points.

Contrarian angles: Consensus reads as bullish flow; that ignores that heavy call buying can be nostalgia or lottery‑ticket hedges with low delta — price impact may be transient as IV is already inflated. The market may be overpricing sustained upside: if implied vol falls 5–10 vol points post‑flow, short call spreads (after IV drop) can be lucrative. Historical parallels: biotech/consumer health spikes driven by option flows often mean‑revert within 4–8 weeks absent fundamentals. Unintended consequence: aggressive dealer hedging can create short squeezes that reverse violently on unwind — size positions to withstand 30–50% intraday moves and set stop thresholds.

Key Decisions for Investors

• Establish a 1–2% NAV position in HIMS using a Mar‑20‑2026 $35/$45 call debit spread (buy $35, sell $45) to limit premium exposure; trim at +50% option ROI or if HIMS equity rises >40% from current levels, stop‑loss the spread at −40% premium loss.
• Allocate 0.8–1.2% NAV to CYTK via a Jan‑16‑2026 $60/$80 call debit spread (long $60, short $80) sized to risk tolerance; take profits at +60% and cut at −45%, and close if a negative clinical update is released within 30 days.
• Establish a relative‑value pair: long HIMS equity equal to 1.0% NAV while shorting TDOC (Teladoc) 0.5% NAV to express consumer telehealth outperformance; rebalance after 30 days or if HIMS outperforms TDOC by >20%.
• If implied volatility drops by ≥5 vol points after these flows, sell 30–60 day call credit spreads on the same tickers (size 0.5% NAV each) to harvest mean reversion; avoid naked short positions and require net portfolio gamma exposure to remain neutral.